$BCRX News

BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen

Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update?

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain

BioCryst (BCRX) Q2 2026 Earnings Call Transcript

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13

Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $20

BioCryst Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call Highlights: Record Revenue and ...

BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (NASDAQ:BCRX) Surges on Q2 Earnings Beat

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BioCryst Appoints David W. Jenkins as Chief Scientific Officer